CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
11 results
Search Results
Now showing 1 - 10 of 11
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, The Persistence of Biologic Therapies for Psoriatic Arthritis(2024); Pamela Díaz<jats:title>Abstract</jats:title> <jats:p>Drug persistence is a crucial measure of long-term efficacy, safety, and patient satisfaction. Lack of persistence can increase healthcare costs and morbidity and mortality rates. This review aimed to consolidate available data on drug persistence for various biological treatments used as the primary intervention for psoriatic arthritis and identify factors associated with nonpersistence. Reports indicate variable 1-year persistence rates for biologic therapies, ranging from 37% to 73%. Specifically, tumor necrosis factor inhibitors have shown fluctuating 1-year persistence rates ranging from 32% to 85%. IL-12/23 and IL-23 inhibitors demonstrate persistence rates of 25% to 89%, whereas data for IL-17 and JAK inhibitors are more limited, ranging from 51% to 77%. Factors such as female sex and a higher burden of comorbidities have been associated with an increased risk of nonpersistence, although evidence regarding other factors remains scarce. The significant variability in reported persistence rates may be attributed to differences in treatment gaps and methodologies across studies. Addressing and mitigating the factors leading to nonpersistence is essential for improving treatment outcomes in psoriatic arthritis.</jats:p>Scopus© Citations 1 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Dermatitis atópica severa en la infancia en la era de la medicina personalizada(2024)9 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ¿Ha disminuido la colectomía por crisis de colitis ulcerosa?(2023)1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Autohemotherapy with ozone as a possible effective treatment for Fibromyalgia(2020)2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders(2022)14Scopus© Citations 15 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Patients with axial spondyloarthritis report significant differences between men and women and high impact of the disease: Large websurvey analysis(2020); Irene E. van der Horst-Bruinsma2Scopus© Citations 13 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto(2020)27Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview(2020)Scopus© Citations 28 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Sex differences in disease activity and efficacy of treatment in spondyloarthritis: is body composition the cause?(2020)21Scopus© Citations 6 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Intranasal delivery of mesenchymal stem cell-derived exosomes reduces oxidative stress and markedly inhibits ethanol consumption and post-deprivation relapse drinking(2019); 1Scopus© Citations 60 5